Success Metrics

Clinical Success Rate
54.5%

Based on 6 completed trials

Completion Rate
55%(6/11)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
5(45%)

Phase Distribution

Ph phase_2
11
100%

Phase Distribution

0

Early Stage

11

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
11(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(6)
Terminated(5)

Detailed Status

Completed6
Terminated5

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
54.5%
Most Advanced
Phase 2

Trials by Phase

Phase 211 (100.0%)

Trials by Status

terminated545%
completed655%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_2

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

NCT01756053
completedphase_2

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697
completedphase_2

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00686933
completedphase_2

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00640185
completedphase_2

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00640419
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01756053Phase 2

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Terminated
NCT00528697Phase 2

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00686933Phase 2

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00640185Phase 2

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00640419Phase 2

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00443391Phase 2

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Completed
NCT00391729Phase 2

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00809510Phase 2

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Terminated
NCT00554385Phase 2

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Terminated
NCT00555204Phase 2

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

Terminated
NCT00069849Phase 2

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11